Search

Hydroxychloroquine

[L14312]** Hydroxychloroquine was granted FDA approval on 18 April 1955.[L8072] A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.[A192546] … [A192132] **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.

Reposal

Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.

Patisiran

Patisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis . It is marketed as Onpattro which is formulated as patisiran within a liposome...

Ulipristal

A recent systematic review proclaimed that the majority of available evidence demonstrates an inhibitory effect on ovulation rather than a post-fertilization effect on the endometrium, which has been heavily … It also binds to glucocorticoid receptor, however compared to mifepristone (a progesterone receptor antagonist), ulipristal is more tolerable and has lower glucocorticoid activity and better binding affinity

Lincomycin

[A190657, A190621] Lincomycin was approved by the FDA on December 29, 1964.[L33214]

Sodium fluorophosphate

Sodium monofluorophosphate is used in OTC dental preparations to help protect against cavities.

Iluzanebart

Lithium carbonate

Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. … Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].